Atopic Dermatitis Clinical Trials in New York, New York

9 studies are recruiting for atopic dermatitis in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

   This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Investigational Site, New York, New York

   Locations

   80 in total

   Run by

   Apogee Therapeutics, Inc.

   See if you can join NCT07003425 on ClinicalTrials.gov

2. Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis

   Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention. The investigators aim to identify an accessible, effective digital health intervention for these patients. The investigators hypothesi…

   Stage

   Not phased

   Ages

   13 to 17

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   2 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT07746427 on ClinicalTrials.gov

3. Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

   This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. Responders (defined as achievi…

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT07242638 on ClinicalTrials.gov

4. A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

   This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

   Stage

   Phase 1

   Ages

   18 to 72

   Site

   OptiSkin Medical, New York, New York

   Locations

   14 in total

   Run by

   Bambusa Therapeutics

   See if you can join NCT06808477 on ClinicalTrials.gov

5. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Sadick Research Group, LLC, New York, New York

   Locations

   85 in total

   Run by

   Apollo Therapeutics Ltd

   See if you can join NCT07599813 on ClinicalTrials.gov

6. A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

   The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

   Stage

   Phase 2

   Ages

   18 to 74

   Site

   Inmagene Site 21, New York, New York

   Locations

   30 in total

   Run by

   Inmagene LLC

   See if you can join NCT07037901 on ClinicalTrials.gov

7. Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

   This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and pediatric participants with atopic…

   Stage

   Phase 1

   Ages

   6 and older

   Site

   Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology, New York, New York

   Locations

   8 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT06504160 on ClinicalTrials.gov

8. Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

   The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

   Stage

   Not phased

   Ages

   12 and older

   Site

   Galderma Investigational Site - 7051, New York, New York

   Locations

   108 in total

   Run by

   Galderma R&D

   See if you can join NCT06988605 on ClinicalTrials.gov

9. A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

   The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring. The study is seeking participants who: * Are currently or recently pregnant * Receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy OR…

   Stage

   Not phased

   Ages

   0 and older

   Site

   Pfizer, New York, New York

   Run by

   Pfizer

   See if you can join NCT05721937 on ClinicalTrials.gov